Prevalence and Predictors of CCI in Patients With Acute Respiratory Failure (CCI)
NCT ID: NCT03851822
Last Updated: 2022-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
127 participants
OBSERVATIONAL
2016-01-01
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Burden of Acute Respiratory Failure in Chinese ICUs: a National Cohort Study
NCT06213779
Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE
NCT02010073
Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure
NCT06511622
Prediction of Functional Outcomes From Chronic Critical Illness
NCT03159208
Epidemiology of Respiratory Insufficiency in Critical Care
NCT01268410
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* consecutively admitted to RICU due to acute respiratory failure (ARF) requiring mechanical ventilation.
Exclusion Criteria
* patient goals of care not consistent with aggressive management
* end stage COPD requiring home oxygen long term therapy or home non invasive ventilation support
* presence of interstitial lung disease
* history of neuromuscular disease
* chest wall deformities
* pregnancy
* chemotherapy or radiotherapy within the past 30 days
* evidence of neurologic injury on CT scan and GCS \< 8
* tracheostomy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Modena and Reggio Emilia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessandro Marchioni
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UModenaReggio3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.